Dabigatran etexilate CAS: 211915-06-9
MF: C34H41N7O5
MW: 627.73
An anticoagulant from the class of direct thrombin inhibitors.

Dabigatran etexilate (CAS 211915-06-9)

Dabigatran etexilate | CAS 211915-06-9 is rated 5.0 out of 5 by 1.
  • y_2021, m_11, d_26, h_18
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.20
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_351724, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 114ms
  • REVIEWS, PRODUCT
loading
5
1
4
0
3
0
2
0
1
0
Application: Dabigatran etexilate is an anticoagulant from the class of direct thrombin inhibitors
CAS Number: 211915-06-9
Purity: ≥98%
Molecular Weight: 627.73
Molecular Formula: C34H41N7O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits
loading

Dabigatran etexilate is the prodrug of the active moiety dabigatran. Dabigatran etexilate has been shown to have slight, but significant drug-drug interactions when used in combination with strong P-glycoprotein inducers or inhibitors such as amiodarone (sc-291891) or rifampicin (sc-200910). It has also been associated with lower rates of stroke and systemic embolism than warfarin (sc-205888), a comparable anticoagulant. Dabigatran etexilate is an inhibitor of Prothrombin.


References

1. Verma, A.K. 2010. Med. J. Aust. 192(7): 407-412. PMID: 2036759
2. Walenga, J.M. and Adiguzel, C. 2010. Int. J. Clin. Pract. 64(7): 956-967. PMID: 20584229
3. Maegdefessel, L. et al. 2010. Vasc Health Risk Manag. 6 : 339-349. PMID: 20531953

Physical State :
Solid
Solubility :
Soluble in DMSO (126 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (12 mg/ml at 25 °C).
Storage :
Store at 4° C
Boiling Point :
827.87° C at 760 mmHg (Predicted)
Density :
1.2 g/cm3
Refractive Index :
n20D 1.62 (Predicted)
pK Values :
pKb: 5.10 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
MDL Number :
MFCD16038312
SMILES :
CCCCCCOC(=O)/N=C(\\C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)/N

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Dabigatran etexilate (CAS 211915-06-9)  Product Citations

See how others have used Dabigatran etexilate (CAS 211915-06-9). Click on the entry to view the PubMed entry .

Citations 1 to 2 of 2 total

PMID: # 28184906  Warkus, ELL. et al. 2017. Toxicol. Sci. 157: 235-245.

PMID: # 31711903  Reprod. Toxicol.

Citations 1 to 2 of 2 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 100ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Preusch Preusch, MR. et al. (PubMed 26392754) reported that Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice. -SCBT Publication Review
Date published: 2015-05-10
  • y_2021, m_11, d_26, h_18
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.20
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_351724, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 7ms
  • REVIEWS, PRODUCT